Rare diseases therapeutics developer Ultragenyx reaffirms 2025 revenue guidance

Ultragenyx Pharmaceutical

04/11/2025 21:44

Overview

Ultragenyx Q3 2025 revenue grows 15% yr/yr to $160 mln

Company reaffirms 2025 revenue guidance of $640 mln to $670 mln

Ultragenyx bolsters balance sheet with $400 mln from Crysvita royalty sale

Outlook

Ultragenyx reaffirms 2025 revenue guidance of $640 mln to $670 mln

Crysvita revenue for 2025 expected between $460 mln and $480 mln

Dojolvi revenue for 2025 expected between $90 mln and $100 mln

Result Drivers

CRYSVITA SALES - Increased Q3 Crysvita revenue driven by product sales in Latin America and Türkiye, and royalties from U.S., Canada, and Europe

ROYALTY SALE - Ultragenyx bolstered balance sheet with $400 mln proceeds from sale of Crysvita royalty interest

CLINICAL PIPELINE - Anticipated launches from late-stage clinical pipeline expected to accelerate growth, per CEO Emil D. Kakkis

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$1.81
Q3 Net Income
-$180 mln
Q3 Operating Expenses
$331 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $80.00, about 58.2% above its November 3 closing price of $33.47

Press Release: ID:nGNXbp3rZY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)